Headquartered in Switzerland a European biotech hub Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully functional research center, and a strong balance sheet the ideal constellation to bringing R amp D efforts to business success.
Quote | Idorsia AG (OTCMKTS:IDRSF)
Last: | $2.25 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $2.25 |
High: | $0 |
Low: | $0 |
Volume: | 1,450 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Idorsia AG (OTCMKTS:IDRSF)
2024-07-11 08:40:40 ET Summary Johnson & Johnson will announce its Q2 2024 results on Wednesday, July 17 before the market opens. In this update, I share what to expect from JNJ's Q2 results and put previous results into perspective. In the main part of the article, I will...
2024-05-22 06:12:16 ET More on Idorsia Idorsia Ltd (IDRSF) Q1 2024 Earnings Call Transcript Idorsia Ltd 2024 Q1 - Results - Earnings Call Presentation Idorsia: Aprocitentan Approval Is A Vital News Historical earnings data for Idorsia Financial inform...
Message Board Posts | Idorsia AG (OTCMKTS:IDRSF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Idorsia AG Company Name:
IDRSF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone pay...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentati...
Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as ...